CN103239646A - Chinese medicine effective part composition for treating leucoderma and preparation method thereof - Google Patents

Chinese medicine effective part composition for treating leucoderma and preparation method thereof Download PDF

Info

Publication number
CN103239646A
CN103239646A CN2013101980144A CN201310198014A CN103239646A CN 103239646 A CN103239646 A CN 103239646A CN 2013101980144 A CN2013101980144 A CN 2013101980144A CN 201310198014 A CN201310198014 A CN 201310198014A CN 103239646 A CN103239646 A CN 103239646A
Authority
CN
China
Prior art keywords
chinese
effective ingredient
chinese medicine
leukodermic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2013101980144A
Other languages
Chinese (zh)
Other versions
CN103239646B (en
Inventor
张群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGZHOU YUNQIAO BIOLOGICAL TECHNOLOGY Co Ltd
Original Assignee
GUANGZHOU YUNQIAO BIOLOGICAL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGZHOU YUNQIAO BIOLOGICAL TECHNOLOGY Co Ltd filed Critical GUANGZHOU YUNQIAO BIOLOGICAL TECHNOLOGY Co Ltd
Priority to CN201310198014.4A priority Critical patent/CN103239646B/en
Publication of CN103239646A publication Critical patent/CN103239646A/en
Application granted granted Critical
Publication of CN103239646B publication Critical patent/CN103239646B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses a Chinese medicine effective part composition for treating leucoderma. The Chinese medicine effective part composition is prepared from semen oroxyli, medulla of stachyurus, sophora fruit, corn stigma and cortex periplocae as raw materials according to certain parts by weight. The Chinese medicine effective part composition disclosed by the invention can be prepared into a medicament for treating leucoderma. The Chinese medicine effective part composition has the effects of activating blood and removing blood stasis, dredging collaterals and smoothing skin, tonifying liver and kidney, and nourishing the blood to expel wind, can be used for significantly treating the leucoderma, and has the advantages of being free of toxic and side effects, and high in safety.

Description

A kind ofly be used for the treatment of leukodermic effective ingredient in Chinese composition and method of making the same
Technical field
The present invention relates to the Chinese medicine composition field, be specifically related to a kind of leukodermic effective ingredient in Chinese composition and method of making the same that is used for the treatment of.
Background technology
Vitiligo is the unusual common skin diseases of a kind of metabolism of pigment.Do not have obvious inducement, doctor trained in Western medicine is thought may be relevant with heredity, autoimmune, endocrine and Nervous and Mental Factors.Because etiology unknown, treatment does not have desirable method yet.Traditional Chinese medical science therapy commonly used is to take TONGQIAOHUOXUE Decoction or LIUWEI DIHUANG TANG, SIWU TANG etc.
Summary of the invention
The object of the present invention is to provide a kind of for the preparation of the treatment leukodermic effective ingredient in Chinese compositions, this effective ingredient in Chinese compositions can be treated vitiligo fast and effectively, has the advantage that therapeutic effect is remarkable, safe, have no side effect.
Above-mentioned purpose of the present invention is achieved by the following technical programs:
The leukodermic effective ingredient in Chinese compositions for the treatment of of the present invention is made by following raw material according to the mass fraction meter: Semen Oroxyli 28, Medulla Stachyuri (Medulla Helwingiae) 25, the Fructus Sophorae 20, Stigma Maydis 15 and Cortex Periplocae 12.
The dosage form that the present invention treats the suitable processing of leukodermic effective ingredient in Chinese compositions is oral liquid.
The leukodermic effective ingredient in Chinese preparation of compositions for the treatment of of the present invention method comprises the steps:
(1) each Chinese medicinal components is pulverized, added 12 times of water gagings, decoct 3 times, decocted 3 hours at every turn; Filter merging filtrate behind the decocting liquid, be evaporated to relative concentration and be 1.15 cream, add ethanol, making it contain the alcohol amount is 62%, and standing over night reclaims ethanol, concentrates;
(2) concentrated solution after will concentrating adds the adjuvant that is fit to according to conventional formulation technology, is processed into oral liquid.
Compared with prior art, the present invention has following beneficial effect:
(1) compositions of the present invention has the effect of nourishing the liver and kidney, yin nourishing hair growth promoting, invigorating qi and benefiting blood, sensible blood stasis dispelling, through test, can treat vitiligo fast.The present invention makes oral liquid to take orally, compares with traditional external-use lotion or acupuncture and moxibustion treatment, can cure vitiligo faster.
(2) present composition has no side effect.
(3) preparation method of the present composition is simple, and the yield height has effectively kept the effective ingredient of medicine.
The specific embodiment
Further explain the present invention below in conjunction with embodiment, but embodiment does not do any type of restriction to the present invention.
Embodiment 1
Get Semen Oroxyli 28g, Medulla Stachyuri (Medulla Helwingiae) 25g, Fructus Sophorae 20g, Stigma Maydis 15g and Cortex Periplocae 12g, be crushed to coarse powder, add 10 times of water gagings, decoct 3 times, decocted 2 hours at every turn; Filter merging filtrate behind the decocting liquid, be evaporated to relative concentration and be 1.3 cream, add ethanol, making it contain the alcohol amount is 60%, and standing over night reclaims ethanol, obtain concentrated solution 1000ml, get simple syrup, add above-mentioned concentrated solution, and transfer pH to 4 with citric acid, adding distil water is to 5000ml, stir, be distributed into behind the fine straining in the 15ml vial, be packaged to be oral liquid.
This product is brown clear liquid, places in half a year and does not produce muddiness, and pH is about 4, total solid about 5%.
Embodiment 2
Clinical observation patient 600 examples, patient all has tangible vitiligo clinical symptoms and makes a definite diagnosis through the clinicist.
The patient is divided into three groups, first group of oral liquid that oral embodiment 1 makes, every day sooner or later each once, each 15ml.Took 20 days.Second group of oral TONGQIAOHUOXUE Decoction, dose is followed the doctor's advice.Take LIUWEI DIHUANG TANG for the 3rd group, dose is followed the doctor's advice.
After 20 days, statistical result sees Table 1.
Criterion of therapeutical effect: produce effects comprises two grades.One-level is that white macula disappears or reduces, and recovers the gross area of the colour of skin greater than 70%; Secondary is that white macula dwindles the normal colour of skin area of recovery less than 70%, and a large amount of pigmentations are arranged in the white macula, grows pigment island or rubescent deepening person.Invalid refer to treatment after, symptom and sign are failed improvement, even increase the weight of.
Table 1
Group The example number Produce effects Invalid Obvious effective rate (%)
1 200 198 2 99
2 200 101 99 50.5
3 200 124 76 62%
By table 1 as can be known, the oral liquid that obtains of embodiment 1 has specially good effect in the treatment vitiligo.Chinese medicine of the present invention was made oral liquid after 20 days, can be in half a year highly significant healing or alleviate the vitiligo disease and its effect is better than TONGQIAOHUOXUE Decoction and LIUWEI DIHUANG TANG commonly used at present.Through follow-up following up a case by regular visits to, the symptom of recurrence does not all appear in the above-mentioned patient who takes embodiment 1 described medicine.
Embodiment 3
The oral liquid administration ICR mice of using embodiment 1 to make, body weight 20 ~ 25g, male and female half and half, successive administration 90d.
Through prerun, the lotion toxicity that embodiment 1 makes is very low, can not survey LD50, measures so mice is carried out maximum dosage-feeding on the one.Maximum dosage-feeding is 100ml/d, observes none example after 90 days and is poisoned to death, and all healthy survival proves that thus the oral liquid that compositions of the present invention is made can not cause toxic and side effects to human body.

Claims (4)

1. the leukodermic effective ingredient in Chinese compositions for the treatment of is characterized in that being made by following raw material according to the mass fraction meter: Semen Oroxyli 28, Medulla Stachyuri (Medulla Helwingiae) 25, the Fructus Sophorae 20, Stigma Maydis 15 and Cortex Periplocae 12.
2. the leukodermic effective ingredient in Chinese compositions for the treatment of according to claim 1 is characterized in that described Chinese medicine composition makes oral liquid.
3. claim 1 or the leukodermic effective ingredient in Chinese preparation of compositions of 2 described treatments method is characterized in that comprising the steps:
(1) each Chinese medicinal components is pulverized, added 10 times of water gagings, decoct 3 times, decocted 2 hours at every turn; Filter merging filtrate behind the decocting liquid, be evaporated to relative concentration and be 1.3 cream, add ethanol, making it contain the alcohol amount is 60%, and standing over night reclaims ethanol, concentrates;
(2) concentrated solution after will concentrating adds the adjuvant that is fit to according to conventional formulation technology, is processed into oral liquid.
4. the application of claim 1 or 2 described effective ingredient in Chinese compositionss is characterized in that described effective ingredient in Chinese compositions is for the preparation of the leukodermic medicine for the treatment of.
CN201310198014.4A 2013-05-26 2013-05-26 Chinese medicine effective part composition for treating leucoderma and preparation method thereof Expired - Fee Related CN103239646B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310198014.4A CN103239646B (en) 2013-05-26 2013-05-26 Chinese medicine effective part composition for treating leucoderma and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310198014.4A CN103239646B (en) 2013-05-26 2013-05-26 Chinese medicine effective part composition for treating leucoderma and preparation method thereof

Publications (2)

Publication Number Publication Date
CN103239646A true CN103239646A (en) 2013-08-14
CN103239646B CN103239646B (en) 2014-08-06

Family

ID=48919749

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310198014.4A Expired - Fee Related CN103239646B (en) 2013-05-26 2013-05-26 Chinese medicine effective part composition for treating leucoderma and preparation method thereof

Country Status (1)

Country Link
CN (1) CN103239646B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105687358A (en) * 2016-03-30 2016-06-22 王银法 Medicine for treating vitiligo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1824247A (en) * 2005-12-22 2006-08-30 夏金陵 Composition formula for treating leucoderma and its preparation method
CN102048872A (en) * 2010-11-24 2011-05-11 荣成市新技术应用研究所 Chinese medicinal composition for treating leucoderma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1824247A (en) * 2005-12-22 2006-08-30 夏金陵 Composition formula for treating leucoderma and its preparation method
CN102048872A (en) * 2010-11-24 2011-05-11 荣成市新技术应用研究所 Chinese medicinal composition for treating leucoderma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
司富春等: "中医治疗白癜风证型和方药分析", 《世界中西医结合杂志》, vol. 7, no. 8, 31 December 2012 (2012-12-31), pages 709 - 712 *
魏飞等: "中医治疗白癜风的研究进展", 《广西中医药》, vol. 35, no. 4, 31 August 2012 (2012-08-31), pages 4 - 5 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105687358A (en) * 2016-03-30 2016-06-22 王银法 Medicine for treating vitiligo

Also Published As

Publication number Publication date
CN103239646B (en) 2014-08-06

Similar Documents

Publication Publication Date Title
CN102274252B (en) Stauntonvine external applied preparation for treating rheumatoid diseases and preparation method thereof
CN103784667A (en) Externally-used Chinese herbal medicine liquor for treating rheumatoidbone disease and preparation and usage method thereof
CN104706953A (en) Traditional Chinese medicine preparation for treating chronic cervicitis
CN102698214B (en) Traditional Chinese medicine for treating migraine and preparation method thereof
CN104147198A (en) Traditional Chinese medicine compound for treating papular acne and preparation thereof
CN103239646B (en) Chinese medicine effective part composition for treating leucoderma and preparation method thereof
CN102526385B (en) Medicament for treating climacteric syndrome
CN105343847A (en) Traditional Chinese medicine composition for treating eczema containing folium artemisiae argyi and preparing method thereof
CN106581299B (en) Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof
CN103239605B (en) Chinese medicine effective part composition for treating hyperostosis and preparation method of Chinese medicine effective part composition
CN103565986B (en) Chinese medicine active part composition for treating Reynolds disease and preparation method thereof
CN103316291A (en) Anti acne of traditional Chinese medicine
CN101983712A (en) Novel medicament for treating coronary heart disease
CN110841007B (en) Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof
CN105169342A (en) Traditional Chinese medicine composition for treating eczema and preparation method thereof
CN104435491A (en) Effective part composition of traditional Chinese medicine for treating parkinson disease and preparation method of effective part composition
CN107233460B (en) External liquid for treating neck, shoulder, waist and leg pain
CN103417900B (en) Composition of effective part of traditional Chinese medicine and preparation method of composition
CN103239571B (en) Chinese medicine effective part composition for treating alopecia areata and preparation method thereof
CN104815132A (en) External lotion for treating low back and leg pain and preparation method
CN103432252A (en) Traditional Chinese medicine granule for treating ox influenza and preparation method thereof
CN103028062B (en) Traditional Chinese medicine for treating ankylosing spondylitis
CN103239564A (en) Chinese medicine effective part composition for treating chronic nephritis and preparation method of Chinese medicine effective part composition
CN103007236A (en) Chinese medicinal composition for treating ankylosing spondylitis
CN103316258B (en) Medicine composition for treating infantile vaginitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140806

Termination date: 20150526

EXPY Termination of patent right or utility model